× An update on sclerostin and kidney

× Fibroblast growth factor 23 and cardiovascular disease in chronic kidney disease; new trends

× Effect and safety of alendronate on bone density in patients with chronic kidney disease; a controlled double blind randomized clinical trial

× Correlation of fibroblast growth factor 23 in chronic kidney disease patients with biochemical parameters and outcomes

× Fibroblast growth factor 23 and cardiovascular events in chronic kidney disease patients

× Vitamin D and chronic kidney disease

× FGF 23 and cardiovascular outcome in chronic kidney disease

× Prevalence and etiologies of acute kidney injury in elderly

× Effectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis patients

× Antioxidant efficacy of vitamin D

× Spontaneous bilateral femoral neck fracture in a man with end-stage renal disease and severe secondary hyperparathyroidism

× The need for a reliable bone biomarker to better assess chronic kidney disease mineral and bone disorder

× Challenging look at therapeutic trend of chronic kidney disease–mineral bone disorder in children

× Bone mineral density and bone metabolism biochemical markers in patients with chronic kidney disease at the hemodialysis treatment

× Relationship of bone density with serum parathyroid hormone in hemodialysis patients; a single center study

× Superior vena cava syndrome complicating calcific uremic arteriolopathy in an ESRD male patient on maintenance hemodialysis following failed kidney transplantation

× Magnesium and parathyroid hormone among end-stage renal disease patients

× Levels of parathyroid hormone and fibroblast growth factor 23 in various stages of pediatric patients with chronic kidney disease

× Secondary hyperparathyroidism among end-stage renal disease patients in Beharlou hospital, Tehran province, Iran